Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Relapsed or Refractory Severe Aplastic Anemia
NCT00195624Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2005
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in aplastic anemia (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Hematological Response at 6 Months. Started Sep 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00195624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195624.